retatrutide case study Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide Long-Term Use: Can You
Description
This could diminish the unique advantage retatrutide holds over dual-agonists like tirzepatide

The mechanisms underlying taste perception changes during GLP-1 therapy are likely multifactorial and indirect rather than representing true gustatory dysfunction

Weight loss may reduce inflammation Fat tissue is not just storage tissue

But others, like the positive impacts we are seeing for individuals who have an alcohol addiction, may point to other impacts of these drugs
Less common but serious side effects included abnormal heart rhythm
